<DOC>
	<DOCNO>NCT00518947</DOCNO>
	<brief_summary>Verapamil find study antimanic activity . Therefore , investigate use verapamil , alone adjunctive treatment , manic patient respond initial adequate trial lithium . Each study phase last three week . Subjects treat openly lithium Phase 1 ( n=45 ) . Those failed respond randomly assign double-blind treatment Phase 2 either verapamil ( n=10 ) continue lithium ( n=8 ) . Phase 2 responder continue medication Phase 3 . Phase 2 nonresponders ( n=10 ) assign combined verapamil/lithium Phase 3 .</brief_summary>
	<brief_title>Pharmacotherapy Treatment-Resistant Mania</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>To eligible study , patient require lifetime diagnosis bipolar 1 schizoaffective disorder , current manic episode meeting DSMIV criterion , rating &gt; /= 7 Raskin Severity Mania Scale &gt; /= 15 BechRafaelsen Mania Scale . Patients exclude : A pattern severe rapidcycling patient consistently fail meet duration criterion discreet episode syndromal mania depression accord DSMIV Sustained drug alcohol abuse within past three year Schizophrenia Organic affective syndrome A presenting episode secondary effect pharmacologic agent The presence significant medical illness would preclude unduly complicate intend pharmacologic management episode In female , refusal use appropriate contraception ; Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Mania</keyword>
	<keyword>Antimanic</keyword>
	<keyword>Verapamil</keyword>
	<keyword>Lithium</keyword>
</DOC>